[1] Lizaola B, Bonder A, Trivedi HD, et al. The diagnostic approach and current management of chylous ascites. Aliment Pharmacol Ther, 2017, 46(9): 816-824.
[2] Møller S, Bendtsen F. The pathophysiology of arterial vasodilatation and hyperdynamic circulation in cirrhosis. Liver Int, 2018, 38(4): 570-580.
[3] Wiest R, Cadelina G, Milstien S, et al. Bacterial translocation up-regulates GTP-cyclohydrolase I in mesenteric vasculature of cirrhotic rats. Hepatology, 2003, 38(6): 1508-1515.
[4] 韩涛, 聂彩云. 肝硬化腹水发病机制研究现状. 实用肝脏病杂志, 2014, 17(4): 4.
[5] Ribera J, Pauta M, Melgar-Lesmes P, et al. Increased nitric oxide production in lymphatic endothelial cells causes impairment of lymphatic drainage in cirrhotic rats. Gut, 2013, 62(1): 138-145.
[6] Hashim SA, Roholt HB, Babayan VK, et al. Treatment ofchyluria and chylothorax with medium-chain triglyceride. N Engl J Med, 1964, 270: 756-761.
[7] Press OW, Press NO, Kaufman SD. Evaluation and management of chylous ascites. Ann Intern Med, 1982, 96(3): 358-364.
[8] Bhardwaj R, Vaziri H, Gautam A, et al. Chylousascites: A review of pathogenesis, diagnosis and treatment. J Clin Transl Hepatol, 2018, 6(1): 105-113.
[9] Kalomenidis I. Octreotide and chylothorax. Curr Opin Pulm Med, 2006, 12(4): 264-267.
[10] Ahn D, Jeon J H, Kim H, et al. Effect of octreotide injection on postoperative drainage after neck dissection: A preliminary report of a prospective, matched case-control study. Clin Exp Otorhinolaryngol, 2016, 9(2): 173-177.
[11] Corley DA, Cello JP, Adkisson W, et al. Octreotide for acute esophageal variceal bleeding: A meta-analysis. Gastroenterology, 2001, 120(4): 946-954.
[12] Cui PJ, Yao J, Zhu Y, et al. Effects of along-acting formulation of octreotide on patients with portal hypertension. Gastroenterol Res Pract, 2017, 2017: 1-6.
[13] Spahr L, Giostra E, Frossard JL, et al. A 3-month course of long-acting repeatable octreotide (sandostatin LAR) improves portal hypertension in patients with cirrhosis: a randomized controlled study. Am J Gastroenterol, 2007, 102(7): 1397-1405.
[14] Chandok N, Kamath PS, Blei A, et al. Randomised clinical trial: the safety and efficacy of long-acting octreotide in patients with portal hypertension. Aliment Pharmacol Ther, 2012, 35(8): 904-912.
[15] Zhang L, Wang X, Chen S, et al. Medium-chain triglycerides attenuate liver injury in lipopolysaccharide-challenged pigs by inhibiting necroptotic and inflammatory signaling pathways. Int J Mol Sci, 2018, 19(11): 3697.
[16] Singh H, Pandit N, Krishnamurthy G, et al. Management of chylous ascites following pancreaticobiliary surgery. JGH Open, 2019, 3(5): 425-428.
[17] Zheng J, Chen YY, Zhang CY, et al. The retrospective research of enteral nutrition with medium-chain triglyceride and total parenteral nutrition support of postoperative chylothorax in adults. SAGE Open Med, 2020, 8: 325.
[18] Zheng J, Chen YY, Zhang CY, et al. Incidence and nutritional management of chylothorax after surgery for congenital heart diseases in children. Heart Surg Forum, 2020, 23(6): E902-E906.
[19] Tulunay G, Ureyen I, Turan T, et al. Chylous ascites: analysis of 24 patients. Gynecol Oncol, 2012, 127(1): 191-197.
[20] Ijichi H, Soejima Y, Taketomi A, et al. Successful management of chylous ascites after living donor liver transplantation with somatostatin. Liver Int, 2008, 28(1): 143-145.
[21] 胡丽娟, 王丽晶, 简易成, 等. 奥曲肽治愈肝硬化乳糜性腹水1例并文献复习. 临床肝胆病杂志, 2012, 28(8): 624-625.
[22] 张海静, 王文睿, 杨岚岚, 等. 奥曲肽治疗肝硬化乳糜样腹水1例. 中南药学, 2019, 17(5): 775-776. |
